Previous 10 | Next 10 |
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 PR Newswire HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target di...
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 PR Newswire HOLON, Israel , Feb. 20 . 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computa...
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer PR Newswire HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) , a clinical-stage cancer immunotherapy company and a pioneer in computatio...
2024-01-30 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-30 08:39:01 ET Iterum Therapeutics ( ITRM ) +61% Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections. Kura Oncology ( KURA ) +16% Reports Positive Preliminary Ziftomen...
2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...
2024-01-08 10:58:36 ET More on Compugen Compugen Ltd. (CGEN) Q3 2023 Earnings Call Transcript Compugen stock rockets 160% on Gilead development deal Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial inform...
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinica...
2023-12-20 08:14:03 ET Polished ( POL ) +108% . Applied UV ( AUVI ) +30% . Longeveron ( LGVN ) +31% Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel- in the Treatment of Mild A...
2023-12-20 05:52:06 ET Stock futures were little changed on Wednesday after the major averages extended the strong year-end rally, as investors leaned towards the idea that the Fed is managing a soft economic slowdown, despite efforts by Fed policymakers to temper expectations for rate...
News, Short Squeeze, Breakout and More Instantly...
Compugen Ltd. Company Name:
CGEN Stock Symbol:
NASDAQ Market:
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 PR Newswire HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pione...
Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, tod...